Stocks in play: PharmaTher Inc
Today submitted its meeting package with the U.S. Food and Drug Administration to discuss advancing KETARX™ into Phase 3 development as a treatment for levodopa-induced dyskinesia in Parkinson’s disease. This Type C meeting allows the Company to discuss with the FDA its plans for a Phase 3 clinical study to support the submission of a new drug application under the 505(b)(2) regulatory pathway for KETARX™ in treating LID-PD. In addition, the Company has requested guidance from the FDA to obtain Fast Track Designation for KETARX™. The Type C meeting is via written responses. The goal date for the FDA in providing its written responses is March 20, 2023. PharmaTher Inc shares C.PHRM are trading unchanged at $0.12.
Read:
Addressing the USA’s 200 to 1 Security Protection Gap is a Serious Concern for Tech Companies
Latest Set of FDA Fast Track Designations Causing Optimism in Biotech Sector
Biotech Sector to Unveil New Data and Developments at 2022 SABCS in San Antonio
Biotech Sector Witnessing Growing Revenue Potential in Ongoing Battle Against Pancreatic Cancer
New Biotech Sector Drug Combinations Target a Drop in Pancreatic Cancer Mortality Rates